60万丁肝患者有药了，完全由中国科学家研制

Core Viewpoint - Huahui Anjian's HH-003 monoclonal antibody has received conditional approval for treating chronic hepatitis D virus (HDV) infection in adults, marking a significant milestone in China's drug innovation and addressing a critical health need for patients previously lacking effective treatments [1][2]. Group 1: Drug Approval and Significance - HH-003 is the first drug for HDV treatment in China and the first monoclonal antibody in the global viral hepatitis field, representing a fully original innovation from China [1][2]. - The approval of HH-003 signifies a breakthrough in addressing chronic HBV and HDV co-infection, which is associated with severe liver-related mortality and progression to liver cancer [2]. Group 2: Research and Development Process - The development of HH-003 was led by a team from Beijing Life Sciences Institute, which conducted the entire process from target discovery to clinical trials, a rare achievement globally [2]. - The clinical research for HH-003 began in 2018, with key data presented at the 2025 American Association for the Study of Liver Diseases meeting, demonstrating significant efficacy and safety compared to control groups [3]. Group 3: Clinical Efficacy - In a phase IIb clinical trial, HH-003 showed a composite endpoint response rate of 44.1%, with a 60% virological suppression rate and a 70% normalization rate of alanine aminotransferase (ALT) after 48 weeks of treatment [3]. - The drug significantly improved liver stiffness in patients with HBV and HDV co-infection, particularly benefiting those with difficult-to-treat liver cirrhosis [3].